



Specific Lipid and Metabolic Profiles of R-CHOP-Resistant Diffuse Large B-Cell Lymphoma Elucidated by Matrix-Assisted Laser Desorption Ionization Mass Spectrometry Imaging and in Vivo Imaging

Barré, Florian P.Y.; Claes, Britt S.R.; Dewez, Frédéric; Peutz-Kootstra, Carine; Munch-Petersen, Helga F.; Grønbæk, Kirsten; Lund, Anders H.; Heeren, Ron M.A.; Côme, Christophe; Cillero-Pastor, Berta

Published in:
Analytical Chemistry

DOI:
[10.1021/acs.analchem.8b02910](https://doi.org/10.1021/acs.analchem.8b02910)

Publication date:
2018

Document version
Publisher's PDF, also known as Version of record

Document license:
[CC BY-NC-ND](#)

Citation for published version (APA):
Barré, F. P. Y., Claes, B. S. R., Dewez, F., Peutz-Kootstra, C., Munch-Petersen, H. F., Grønbæk, K., Lund, A. H., Heeren, R. M. A., Côme, C., & Cillero-Pastor, B. (2018). Specific Lipid and Metabolic Profiles of R-CHOP-Resistant Diffuse Large B-Cell Lymphoma Elucidated by Matrix-Assisted Laser Desorption Ionization Mass Spectrometry Imaging and in Vivo Imaging. *Analytical Chemistry*, 90(24), 14198-14206.
<https://doi.org/10.1021/acs.analchem.8b02910>

Specific Lipid and Metabolic Profiles of R-CHOP-Resistant Diffuse Large B-Cell Lymphoma Elucidated by Matrix-Assisted Laser Desorption Ionization Mass Spectrometry Imaging and in Vivo Imaging

Florian P.Y. Barré,^{†,‡} Britt S.R. Claes,^{†,‡} Frédéric Dewez,[†] Carine Peutz-Kootstra,[‡] Helga F. Munch-Petersen,[§] Kirsten Grønbaek,^{||,⊥} Anders H. Lund,[⊥] Ron M.A. Heeren,^{†,Ⓜ} Christophe Côme,^{||,⊥,Ⓜ} and Berta Cillero-Pastor^{*,†,Ⓜ}

[†]The Maastricht Multimodal Molecular Imaging Institute (M4I), Division of Imaging Mass Spectrometry, Maastricht University, 6229 ER Maastricht, The Netherlands

[‡]Department of Pathology, Maastricht University Medical Center, Cardiovascular Research Institute Maastricht, 6229 HX Maastricht, The Netherlands


[§]Department of Haematology and Department of Pathology, Rigshospitalet, 2100 Copenhagen, Denmark

^{||}Epigenomlaboratoriet, Rigshospitalet Dept. 3733, Bartholin Institute, Copenhagen Biocenter, 2200 Copenhagen, Denmark

[⊥]Biotech Research and Innovation Centre (BRIC), University of Copenhagen, 2200 Copenhagen, Denmark

Supporting Information

ABSTRACT: Diffuse large B-cell lymphoma (DLBCL) is the most common B-cell non-Hodgkin lymphoma. To treat this aggressive disease, R-CHOP, a combination of immunotherapy (R; rituximab) and chemotherapy (CHOP; cyclophosphamide, doxorubicin, vincristine, and prednisone), remains the most commonly used regimen for newly diagnosed DLBCLs. However, up to one-third of patients ultimately becomes refractory to initial therapy or relapses after treatment, and the high mortality rate highlights the urgent need for novel therapeutic approaches based upon selective molecular targets. In order to understand the molecular mechanisms underlying relapsed DLBCL, we studied differences in the lipid and metabolic composition of nontreated and R-CHOP-resistant tumors, using a combination of in vivo DLBCL xenograft models and mass spectrometry imaging. Together, these techniques provide information regarding analyte composition and molecular distributions of therapy-resistant and sensitive areas. We found specific lipid and metabolic profiles for R-CHOP-resistant tumors, such as a higher presence of phosphatidylinositol and sphingomyelin fragments. In addition, we investigated intratumor heterogeneity and identified specific lipid markers of viable and necrotic areas. Furthermore, we could monitor metabolic changes and found reduced adenosine triphosphate and increased adenosine monophosphate in the R-CHOP-resistant tumors. This work highlights the power of combining in vivo imaging and MSI to track molecular signatures in DLBCL, which has potential application for other diseases.



Diffuse large B-cell lymphoma (DLBCL) is the most common B-cell non-Hodgkin's lymphoma (NHL) throughout the world, comprising 30–35% of all NHLs, with approximately 72 580 new cases and 20 150 deaths estimated for 2016.¹ Implemented 20 years ago, R-CHOP, a combination of immunotherapy (R: rituximab, targeting the cell surface protein CD20 expressed by B-cell lymphoma) and chemotherapy (CHOP: cyclophosphamide, doxorubicin, vincristine, and prednisone), remains the most commonly used regimen for newly diagnosed advanced DLBCLs. This therapy has considerably improved treatment response,^{2–5} but DLBCL is a biologically aggressive disease and up to one-third of patients

becomes refractory to initial therapy⁶ and displays a poor survival outcome.^{7,8}

The high mortality rate in patients with relapsed DLBCL highlights the urgent need for novel therapeutic approaches based upon selective molecular targets. Therefore, it is of high importance to enhance our understanding of the various mechanisms leading to tumor resistance/relapse in order to develop efficient therapies against refractory/relapsing

Received: June 27, 2018

Accepted: November 13, 2018

Published: November 13, 2018

DLBCL. To do so, two criteria are critical, (i) to precisely monitor DLBCL cells' response to R-CHOP treatment and tumor progression, and (ii) to analyze global and local molecular tumor profiles in relation to treatment response.

Implemented for the first time two decades ago, live in vivo bioluminescent imaging (BLI) has allowed researchers to detect living cells in rodents in a noninvasive manner.⁹ Cells are genetically modified in order to express a luciferase enzyme, which, after injection of luciferin in the animal, will lead to the emission of a luminescent signal. This signal is then acquired and quantified by an in vivo imaging system (IVIS). Of note, in cancer xenograft models, it also allows precise monitoring and quantification of tumor development from earlier stages and more accurately than caliper measurements.¹⁰ Moreover, in the past decade, scientists have generated lentiviral vectors coupling fluorescent markers and luciferase, allowing for the stable generation of luminescent variants of almost any cancer cell line.¹¹ Such models have been previously shown to efficiently monitor lymphoma cells reaction to treatment in murine models.¹²

Mass spectrometry imaging (MSI) is an analytical tool capable of identifying and mapping hundreds of molecules in a single experiment from thin, biological sections. MSI differs from other imaging techniques as it is a label-free method used to study molecules ranging from proteins and peptides¹³ to lipids,¹⁴ metabolites,¹⁵ and drugs.¹⁶ MSI is commonly used to study and characterize different types of cancer.^{17,18}

Matrix-assisted laser desorption/ionization (MALDI) is one of the main ionization techniques used in the MSI field. A thin layer of matrix is deposited on-top of the sample in order to help ionization and desorption of the molecules. Then, a laser shoots across the tissue section recording the biomolecular profile (mass-to-charge ratio and relative intensity) of each acquired position. Dedicated software allows the generation of images at a given pair of *x*- and *y*-coordinates. MALDI-MSI¹⁹ offers a very high spatial resolution (up to 1–5 μm)^{20,21} and an acquisition speed of 50 pixels per second,²² providing histological information at the biomolecular level.

Recent studies have demonstrated the advantages of combining in vivo imaging and MSI in cancer research. Indeed, Hinsenkamp et al. demonstrated the potential of the ROCK1/2 inhibitor Fasudil in a gastric cancer model either by positron emission tomography–computed tomography (PET/CT) in vivo imaging or MALDI-MS imaging.²³ Jiang et al. have identified specific lipid profiles of hypoxic regions in a breast cancer model by combining bioluminescence in vivo imaging and MSI.²⁴ In this work, we demonstrate the potential of using BLI to follow the response to R-CHOP treatment and MALDI-MSI to characterize the molecular profiles of resistant tumors.

Our results reveal distinctive signatures of lipids and metabolites in R-CHOP-resistant lymphoma tumors that could help to identify new targets involved in treatment resistance. Furthermore, our studies demonstrate that BLI–MALDI-MSI combined can be applied to study molecular and metabolic progression of many other diseases.

■ EXPERIMENTAL SECTION

The U2932 DLBCL cell line was obtained from American Type Culture Collection, USA. A luminescent and fluorescent variant of the cell line was generated, on the basis of the pFULT lentiviral system, as previously published (details in the Supporting Information).^{24,25}

Generation of DLBCL Xenografts. The 10^7 freshly harvested U2932 pFULT cells (200 μL from a stock solution of 5×10^7 cells/mL in PBS) were subcutaneously injected in the right flank of 40 NMRI-nude adult females (Janvier Laboratories, France). Following injection, in vivo luminescence imaging was used to follow tumor development using an IVIS Lumina II (Caliper Life Sciences, USA). Mice were checked daily to detect any sign of discomfort or sickness and sacrificed by cervical dislocation if such condition would appear. Of the 40 injected mice, 33 developed tumors and did not present any side-effects. Of these 33 tumorous mice, 5 were left untreated as controls, and 28 were treated with an R-CHOP regiment once the tumor had reached a total luminescence signal of at least 3×10^{10} photons/second. One cycle of R-CHOP therapy was defined as three consecutive repeats of a weekly procedure, from indicated time-points, based on published protocols.^{26,27} One procedure consists of a single Rituximab (MabThera subcutaneous, Roche, Switzerland) subcutaneous injection on day 1, dosed at 25 mg/kg combined with CHOP treatment as follows: cyclophosphamide (Sigma-Aldrich, C0768, USA) intraperitoneal (i.p.), day 2, dosed at 40 mg/kg; doxorubicin (Sigma-Aldrich, D2975000, USA), i.p., day 2, dosed at 3.33 mg/kg; vincristine (Sigma-Aldrich, V0400000, USA) i.p., day 2, dosed at 0.2 mg/kg; and prednisone (Sigma-Aldrich, P6254, USA), oral gavage from day 1 to 5 inclusive, dosed at 0.2 mg/kg. The tumors were harvested and immediately heat-stabilized (Stabilizer System, Denator, Sweden) in order to preserve their molecular integrity before being snap-frozen in isopentane and then stored at -80°C until MSI analysis.

Mass Spectrometry Imaging. The 12 μm consecutive sections were used in order to obtain technical triplicates of each tumor and type of MSI experiment (lipids positive mode, lipids negative mode, and metabolites).

Lipid Analysis. Prior to matrix application, the samples were dried for 15 min. Norharmane (Sigma-Aldrich, Gillingham, UK) matrix was applied to sections at 7 mg/mL in 2:1 chloroform:methanol (v/v) using the TM-Sprayer M3 (HTX Technologies LLC, Carrboro, USA). Eleven layers were applied with a drying time of 30 s between each layer using a nozzle temperature of 30°C with a flow rate of 120 $\mu\text{L}/\text{min}$. The velocity was set at 1200 mm/min combined with a track passing of 3 mm allowing homogeneous matrix application.²⁸

Metabolite Analysis. *N*-(1-Naphthyl) ethylenediamine dihydrochloride (NEDC) (Sigma-Aldrich, Gillingham, UK) matrix was applied to sections at 7 mg/mL in 70% methanol (v/v). The spray parameters were the same as for the lipids with the only difference that the nozzle temperature was set to 85°C . 9-Aminoacridine hydrochloride monohydrate (9AA) (Sigma-Aldrich, Gillingham UK) matrix was applied at 7 mg/mL in 70% ethanol (v/v) using the SunCollect (SunChrom, Friedrichsdorf, Germany). Twenty layers were applied with a flow rate of 40 $\mu\text{L}/\text{min}$ and a Z offset of 25 mm. The velocity was set at 1250 mm/min combined with a line distance of 2 mm.

Lipids were detected using both positive and negative ion polarities and metabolites only in the negative mode using a Bruker RapifleX MALDI Tissue-typer instrument operating in reflectron mode (Bruker Daltonik GmbH, Germany) and an Orbitrap Elite hybrid ion trap mass spectrometer (Thermo Fisher Scientific, Bremen, Germany) (see the Supporting Information).




Figure 1. In vivo R-CHOP resistance of DLBCL cells monitored by in vivo imaging and classified by MSI. (A) Schematic of the experimental design and workflow. (B) Overview of the mice used for this study. (C) Averaged tumoral development of the 5 untreated mice. Points and bars are, respectively, mean \pm SD at indicated time-points. (D) Tumoral development of R-CHOP-resistant mice. Stars indicate initiation of a R-CHOP regimen, lasting 3 weeks. Final point for each mouse indicates tumor not responding to R-CHOP therapy anymore.

Imaging Processing. FlexImaging v4.1 (Bruker Daltonik GmbH, Bremen, Germany) and SCiLS lab 2016b (SCiLS GmbH, Bremen, Germany) were used to process the imaging data acquired with the Bruker RapifleX. Thermo Xcalibur 3.0.63 (Thermo Fisher Scientific, Bremen, Germany) was used to analyze the Orbitrap imaging data. Principal component analysis (PCA), hierarchical clustering analysis (HCA), and linear discriminant analysis (LDA) were performed after peak picking using an in-house-built ChemomeTricks toolbox for MATLAB version 2014a (The MathWorks, Natick, USA).²⁹

On-tissue pixels were selected as regions of interest (ROIs) and assigned to a category representing the untreated and resistant classes, respectively. PCA-LDA was performed with one-fourth of the number of features as the number of

functions for the LDA,³⁰ which were 337 functions for lipids in negative polarity, 338 functions for lipids in positive polarity, and 357 functions for metabolites. The scores that described the different discriminant functions (DF) were adjusted to Gaussian curves following a normal distribution and projected onto ROIs. DF is a variable that was composed to maximize the variance between the groups and to minimize the variance within the groups.

The lipids and metabolites were then identified using tandem MS as well as the databases, LIPID MAPS Structure Database (<http://lipidmaps.org>), ALEX123 lipid database (<http://alex123.info/ALEX123/MS.php>),³¹ METLIN database (<https://metlin.scripps.edu>), and Human Metabolome Database (<http://www.hmdb.ca/>).




Figure 2. Discriminating untreated and R-CHOP-resistant tumors based on the lipid signature in negative polarity. (A) DF1 scaled loading spectrum. (B) DF1 score projection. (C) Single peak intensity plots of PE 36:2 [M - H]⁻ (left) and PE 18:0_22:5 [M - H]⁻ (right).

After acquisition, the tissue sections were analyzed by fluorescent microscopy and stained for histological annotation. For more details about material and methods, please see the [Supporting Information](#).

RESULTS AND DISCUSSION

In Vivo Imaging Monitoring To Follow the Tumor Growth. We selected the U2932 DLBCL cell line to generate our in vivo model (Figure 1A), as it presents a high expression of v-myc avian myelocytomatosis viral oncogene homologue (MYC) and B-cell lymphoma 2 (BCL2),³² a hallmark of refractory/relapse DLBCL patients.³³ Using the pFULT lentiviral system, we generated a variant of this cell line stably and constitutively expressing luciferase 2 as well as TdTomato (Figure 1A). In a pilot experiment, we validated the possibility of monitoring tumor development from these xenografts and observed that tumors should reach a minimum total signal of 3×10^{10} photons/second before starting R-CHOP therapy in order to obtain refractory/relapsing tumors (data not shown). Then, we injected 40 mice, leading to 33 animals developing

tumors without presenting side-effects; 5 control mice were not treated (Figure 1B), presenting constant tumor growth (Figures 1C and S1); and 28 were treated with the R-CHOP regimen. As our aim was to characterize R-CHOP resistance, we defined resistant tumors as those presenting regular tumor growth after serial regimens of R-CHOP treatment (Figure 1D). Under this criterion, 4 of the 28 injected, treated mice showed R-CHOP-resistant tumors (Figures 1D and S1).

Differential Lipid Profiles between Untreated and Relapsing Tumors Revealed by MALDI-MSI. Different lipid profiles between untreated and R-CHOP-resistant tumors were revealed by MALDI-MSI (100 × 100 μm raster size). Both ion polarities allowed for the visualization of different molecular classes. In negative-ion mode (Figure 2, Table 1), we detected phosphatidylinositols (PI), phosphatidylethanolamines (PE), phosphatidylserines (PS), phosphatidylglycerols (PG), and cardiolipins (CL). Principal component analysis followed by linear discriminant analysis (PCA-LDA) was used for data reduction and to look for specific profiles of each condition (Figure 2A).

Table 1. Lipid Assignments Based on MS/MS and High Mass Resolution MSI Experiments

<i>m/z</i> value	Assignment	Designation	Condition	DF1	PPM error
524.37	LPC 18:0	[M+H] ⁺	Relapsed		0.39
725.56	SM (34:1:2)	[M+Na] ⁺	Relapsed		0.28
756.55	PC 32:0 (16:0/16:0)	[M+Na] ⁺	Relapsed		0.50
786.60	PC 36:2	[M+H] ⁺	Untreated		1.00
796.53	PC 34:2	[M+K] ⁺	Untreated		0.66
808.58	PC 36:2	[M+Na] ⁺	Relapsed		0.87
832.58	PC 38:4	[M+Na] ⁺	Relapsed		0.65
834.58	PC O ₃₈ :4	[M+K] ⁺	Relapsed		1.17
687.54	[M-CH ₃] ⁻ Fragment from <i>m/z</i> SM d18:1_16:0	[M-H] ⁻	Relapsed		0.52
689.56	[M-CH ₃] ⁻ Fragment from <i>m/z</i> SM d18:0_16:0	[M-H] ⁻	Relapsed		1.29
714.51	PE 16:0_18:2	[M-H] ⁻	Untreated		-0.31
738.51	PE 16:0_20:4	[M-H] ⁻	Untreated		-0.03
740.52	PE 36:3	[M-H] ⁻	Untreated		-0.31
742.54	PE 36:2	[M-H] ⁻	Untreated		-0.03
747.52	PG 16:0_18:1	[M-H] ⁻	Untreated		-0.56
766.54	PE 18:0_20:4	[M-H] ⁻	Relapsed		-0.70
770.57	DMPE 36:2	[M-H] ⁻	Untreated		-0.04
773.53	PG 36:2	[M-H] ⁻	Untreated		-0.36
786.53	PS 18:0_18:2	[M-H] ⁻	Untreated		-0.21
792.55	PE 18:0_22:5	[M-H] ⁻	Relapsed		-1.00
821.53	PG 18:1_22:5	[M-H] ⁻	Relapsed		-1.14
823.55	PG 40:5	[M-H] ⁻	Relapsed		-0.70
838.56	PS 18:0_22:4	[M-H] ⁻	Relapsed		-0.53
843.52	PG 20:4_22:5	[M-H] ⁻	Relapsed		-0.89
857.52	PI 16:0_20:4	[M-H] ⁻	Relapsed		-1.27
885.55	PI 18:0_20:4	[M-H] ⁻	Untreated		-1.07
909.55	PI 18:0_22:6	[M-H] ⁻	Relapsed		-1.17
913.58	PI 18:0_22:4	[M-H] ⁻	Relapsed		-1.19
1447.96	CL (18:2)4	[M-H] ⁻	Untreated		-0.97
1449.98	CL (18:1)1_(18:2)3	[M-H] ⁻	Untreated		-0.91
1452.00	CL (18:1)2_(18:2)2	[M-H] ⁻	Untreated		-0.45
1473.98	CL (18:1)2_(18:2)2	[M+Na-2H] ⁻	Relapsed		-0.44
1478.01	CL 72:4	[M+Na-2H] ⁻	Untreated		-0.86
1485.92	CL (18:2)4	[M+K-2H] ⁻	Untreated		-0.62
1487.94	CL (18:1)1_(18:2)3	[M+K-2H] ⁻	Untreated		0
1489.95	CL (18:1)2_(18:2)2	[M+K-2H] ⁻	Untreated		-0.13
1513.95	CL (18:2)3_(20:2)1	[M+K-2H] ⁻	Untreated		-0.4
1515.97	CL (18:1)1_(18:2)2_(20:2)1	[M+K-2H] ⁻	Untreated		-0.24

The DF1 of lipids in negative mode described 1.5% of the total variance used for the LDA. The projection of the DF1 scores revealed different biomolecular profiles for the untreated and resistant tumors (Figure 2B). Of importance, different lipid families appeared to be specific to each condition (Table 1). PI and most PG species were specific of R-CHOP-resistant tumors, whereas most PE and CL species were predominantly detected in the untreated condition (Figure 2A,C). The higher presence of PI in the relapsed condition is biologically relevant as phosphoinositide 3-kinase, a key cellular signaling mediator of this lipid family, which has been shown to be involved in DLBCL pathogenesis by having a role in protein trafficking³⁴ and is currently being investigated as a target for refractory/relapsed DLBCL.³⁵ Of note, we also observed some lipid fragments from sphingomyelins (SM) d18:1_16:0 (*m/z* 687.54, [M - H]⁻), exclusively localized in certain tumor regions.

In the positive-ion mode, different lipid classes, such as phosphocholines (PC), SM, and PE, were detected (Table 1). The DF1 was discriminated between the two conditions (Figure 3A,B), describing 1.1% of the total variance used for the LDA. Likewise, individual lipids were more abundant in one condition compared to the other (Table 1). For instance, PC 34:2 (*m/z* 796.53, [M + K]⁺) was specific to the untreated DLBCL, whereas PC O₃₈:4 (*m/z* 834.58, [M + K]⁺) was

more present in the resistant tumors (Figure 3A,C). Most of the sodiated lipid adducts were detected in the resistant condition. An interesting case is PC 36:2, predominantly detected as *m/z* 786.60 [M + H]⁺ in untreated tumors and as *m/z* 808.58 [M + Na]⁺ in the resistant condition (Table 1). Other examples are SM (34:1:2) (*m/z* 725.56, [M + Na]⁺) (Figure S3) and PC 38:4 (*m/z* 832.58, [M + Na]⁺), found to be more present in the relapsed tumors. These observations suggest that a higher content of Na⁺ would be involved in R-CHOP resistance mechanisms. Chughtai et al.³⁶ found that the SM d18:1/16:0 sodium adduct primarily colocalized with hypoxic and necrotic tumor regions, agreeing with Irigoyen et al.³⁷ who showed a correlation between hypoxia with the aggressiveness, metastatic spread, and relapse of solid tumors.

Tumor Heterogeneity Characterized by MSI Lipidomic Profiles. Fluorescence microscopy experiments confirmed that all tumoral cells expressed TdTomato protein, which was introduced in our DLBCL human cell line model (Figures 1 and S2). This excluded the possibility of having resected murine tissue with the tumor. Second, the H&E stained slides were annotated by a pathologist, and we identified these areas as necrotic regions (Figure S4A). MSI of the treatment-resistant tumors (tumors 272 and 285) distinguished between viable and necrotic regions, which were similar to pathologist annotations in H&E-stained slides (Figure S4). PCA was performed to evaluate specific lipid profiles linked to these different tumor areas (Figure S4B,C). In order to further study tumor heterogeneity and identify characteristic lipids of each area, we performed experiments at a higher spatial (30 μm) and mass resolution (240 000 resolving power at *m/z* 400). In Figure 4, individual channels were plotted to represent the specific lipid distribution in viable and necrotic parts of resistant tumors. In the negative mode, we were able to discriminate viable/necrotic areas, with a higher presence of PI 18:0_20:4 (*m/z* 885.55, [M - H]⁻) in the viable regions, while the SM d18:1_16:0 fragment (*m/z* 687.54, [M - H]⁻) was a marker for the dead cell state (Figure 4A). In the positive mode, we observed that PC 34:2 (*m/z* 796.53, [M + K]⁺) was a marker of the viable but R-CHOP-resistant tumor tissue, whereas LPC 18:0 (*m/z* 524.37, [M + H]⁺) was specific to the necrotic part (Figure 4B). This finding confirms previous studies that detected high PC levels in non-necrotic tumor regions, revealing importance of PCs in the following the tumor progression.³⁸ In fact, Glunde et al. described the importance of targeting choline metabolites for early cancer detection.³⁹

As mentioned above, most of the sodiated adducts were assigned to the resistant condition. In addition, the distribution of these sodiated species seemed to be specific to the necrotic areas of resistant tumors; SM (34:1:2) (*m/z* 725.56, [M + Na]⁺) (Figure S3), PC 36:2 (*m/z* 808.58, [M + Na]⁺), PC 32:0 (16:0/16:0) (*m/z* 756.55, [M + Na]⁺), and PC 38:4 (*m/z* 832.58, [M + Na]⁺) are several examples. Our observations are in agreement with those of Amstalden van Hove et al., who also observed higher levels of Na⁺ in the necrotic tumor regions by MSI.³⁸ It is possible, that high Na⁺ levels lead to necrosis, or that this high sodium presence could be a consequence of the cell death process. These high sodium levels may also correlate with a decrease in Na⁺/K⁺ pump activity and an increase in cell permeability.^{34,36} Interestingly, higher potassiated lipid species were found in viable compared to necrotic tissue, such as PC 34:2 (*m/z* 796.53, [M + K]⁺). This is supported as well by Summers et al., who showed that




Figure 3. Discriminating untreated and R-CHOP-resistant tumors based on the lipid signature in positive polarity. (A) DF1 scaled loading spectrum. (B) DF1 score projection. (C) Single peak intensity plots of PC 34:2 $[M + K]^+$ (left) and PC O_{38:4} $[M + K]^+$ (right).

higher K^+ levels were found in viable tumor regions compared to necrotic areas.⁴⁰ Our results suggest that the presence of sodiated lipids could indicate a good response to R-CHOP therapy.

Metabolic Changes in Relapsed DLBCL Tumors. After we optimized our method for MALDI-MSI detection of small molecules using 9-AA and NEDC,^{41,42} we observed a higher signal-to-noise ratio for metabolites, such as adenosine monophosphate (AMP, m/z 346.06), adenosine diphosphate (ADP, m/z 426.02), and adenosine triphosphate (ATP, m/z 505.99), using NEDC. In addition, the matrix peaks were less abundant in the mass spectrum with NEDC compared to 9-AA, which helped to avoid matrix interferences (Figure S5). NEDC allowed the analysis of lipids and metabolites in a single experiment. Hence, we performed analysis targeting metabolites using NEDC at a raster size of 100 μ m.

PCA-LDA showed a separation between the untreated and resistant tumors (Figure 5A). The DF1 described 2.0% of the total variance used for the LDA. The DF1 score projections looked similar for all triplicates and molecular classes (Figure S6). In addition, we identified metabolites that discriminated

untreated from R-CHOP resistant tumors (Figure 5B). As an example, ATP was more abundant in the untreated sections (Figure 5C), whereas AMP presented a relatively higher intensity in the viable areas of the R-CHOP-resistant tumors (Figure S7). Previous studies reported that ATP consumption serves to increase glucose flux to satisfy the energetic and biosynthetic demands of a rapidly proliferating cancer cell.⁴³ ATP production is associated with CLs via the electron transport chain, which is involved in oxidative phosphorylation,^{42,43} a more efficient pathway for ATP production than glycolysis.⁴⁴ We found that most of the CL species were more abundant in the untreated samples, as shown in the DF spectrum of the lipids in negative mode (Figure 2A). CLs are a class of mitochondrion-specific anionic phospholipids and play multiple structural and functional roles in bioenergetics. According to Kiebish et al., environmental factors, including necrosis and hypoxia, could alter CL content and/or composition, which could affect tumor initiation or progression.⁴⁵ Importantly, CHOP has been suggested to influence metabolism and the mitochondrial state in lymphoma xenografts in vivo.^{46,47} Indeed, differences in




Figure 4. Intratumor heterogeneity. (A) Negative-ion mode images show the spatial distribution of PI 18:0_20:4 (left) and SM d18:1_16:0 (middle) in viable and necrotic regions, respectively, determined by H&E staining (right). (B) Positive-ion mode images show the spatial distribution of PC 34:2 (left) and LPC 18:0 (middle), which correlated to viable and necrotic areas, respectively, again determined by H&E staining (right).

metabolism and mitochondrial state have been characterized in lymphoma patients.^{38,39}

Regarding glycerophosphocholine, we observed that this major form of choline storage (shown as dysregulated in cancer metabolism^{38,48,49} by others) was specific to resistant tumors. Interestingly, glycerophosphocholine has been associated with poor prognosis in breast cancer.⁵⁰ Our findings suggest that the highest level of glycerophosphocholine present in the resistant tumors could be linked to PCs, which were also more abundant in the resistant tissues. Other groups have

described a relationship between differential biomolecular profiles and cell density, which might be related to a higher cell division rate in aggressive tumors.^{51,52}

CONCLUSION

Our approach shows the potential of combining in vivo imaging and MSI to investigate molecular differences associated with successful and nonresponsive cancer treatment. To our knowledge, our study is the first that combines bioluminescence in vivo imaging, for characterization of lipids




Figure 5. Metabolic classification of nontreated and R-CHOP-resistant tumors. (A) DF1 scaled loading spectrum. (B) Metabolite assignments. (C) Single peak intensity plots showing a relative predominance of ATP in untreated tumors.

and metabolic profiles associated with R-CHOP resistant tumors. Moreover, specific molecular signatures could be associated with intratumor heterogeneity. MSI is a robust tool to discover new markers and signatures of lymphoma, which could be applied to investigate other cancers and their specific treatment success/resistance.

■ ASSOCIATED CONTENT

Supporting Information

The Supporting Information is available free of charge on the ACS Publications website at DOI: [10.1021/acs.analchem.8b02910](https://doi.org/10.1021/acs.analchem.8b02910).

Materials and methods, MALDI-MSI, representative IVIS acquisitions, presence of TdTomato fluorescent protein, single intensity plot, intratumor heterogeneity, matrix optimization, discriminant function projections, and tumor heterogeneity (PDF)

■ AUTHOR INFORMATION

Corresponding Author

*Tel.: +31 43 388 4 839; E-mail: b.cillero-pastor@maastrichtuniversity.nl.

ORCID

Ron M.A. Heeren: [0000-0002-6533-7179](https://orcid.org/0000-0002-6533-7179)

Berta Cillero-Pastor: [0000-0002-7407-1165](https://orcid.org/0000-0002-7407-1165)

Author Contributions

#F.P.Y.B. and B.S.R.C. contributed equally to this work.

Author Contributions

†C.C. and B.C.P. contributed equally to this work.

Notes

The authors declare no competing financial interest.

■ ACKNOWLEDGMENTS

This work has been financially supported by the Dutch Province of Limburg as part of the “LINK” program and by the European Union’s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement 642414. We thank Dr. Kevin Knoops (M4I, division of Nanoscopy, Maastricht University) for his help with fluorescence microscopy experiments. The in vivo experiments have been supported by the Danish Council for Independent Research (Sapere Aude program), the Novo Nordisk Foundation, the Lundbeck Foundation, and the Danish Cancer Society, and the Grønbæk laboratory was supported by the Danish Cancer Society (R132-A8315).

■ REFERENCES

- (1) Siegel, R. L.; Miller, K. D.; Jemal, A. *Ca-Cancer J. Clin.* **2016**, *66*, 7–30.
- (2) Pfreundschuh, M.; Kuhnt, E.; Trumper, L.; Osterborg, A.; Trneny, M.; Shepherd, L.; Gill, D. S.; Walewski, J.; Pettengell, R.; Jaeger, U.; Zinzani, P. L.; Shpilberg, O.; Kvaloy, S.; de Nully Brown, P.; Stahel, R.; Milpied, N.; Lopez-Guillermo, A.; Poeschel, V.; Grass, S.; Loeffler, M.; Murawski, N. *Lancet Oncol.* **2011**, *12*, 1013–1022.
- (3) Fisher, R. I.; Gaynor, E. R.; Dahlborg, S.; Oken, M. M.; Grogan, T. M.; Mize, E. M.; Glick, J. H.; Coltman, C. A., Jr.; Miller, T. P. N. *Engl. J. Med.* **1993**, *328*, 1002–1006.
- (4) Coiffier, B.; Thieblemont, C.; Van Den Neste, E.; Lepeu, G.; Plantier, I.; Castaigne, S.; Lefort, S.; Marit, G.; Macro, M.; Sebban, C.; Belhadj, K.; Bordessoule, D.; Ferme, C.; Tilly, H. *Blood* **2010**, *116*, 2040–2045.
- (5) Salles, G.; Barrett, M.; Foa, R.; Maurer, J.; O’Brien, S.; Valente, N.; Wenger, M.; Maloney, D. G. *Adv. Ther.* **2017**, *34*, 2232–2273.
- (6) Roschewski, M.; Staudt, L. M.; Wilson, W. H. *Nat. Rev. Clin. Oncol.* **2014**, *11*, 12–23.

- (7) Blay, J.; Gomez, F.; Sebban, C.; Bachelot, T.; Biron, P.; Guglielmi, C.; Hagenbeek, A.; Somers, R.; Chauvin, F.; Philip, T. *Blood* **1998**, *92*, 3562–3568.
- (8) Martelli, M.; Ferreri, A. J.; Agostinelli, C.; Di Rocco, A.; Pfreundschuh, M.; Pileri, S. A. *Critical reviews in oncology/hematology* **2013**, *87*, 146–171.
- (9) Contag, C. H.; Spilman, S. D.; Contag, P. R.; Oshiro, M.; Eames, B.; Dennery, P.; Stevenson, D. K.; Benaron, D. A. *Photochem. Photobiol.* **1997**, *66*, 523–531.
- (10) Sweeney, T. J.; Mailander, V.; Tucker, A. A.; Olomu, A. B.; Zhang, W.; Cao, Y.; Negrin, R. S.; Contag, C. H. *Proc. Natl. Acad. Sci. U. S. A.* **1999**, *96*, 12044–12049.
- (11) Liu, H.; Patel, M. R.; Prescher, J. A.; Patsialou, A.; Qian, D.; Lin, J.; Wen, S.; Chang, Y. F.; Bachmann, M. H.; Shimono, Y.; Dalerba, P.; Adorno, M.; Lobo, N.; Bueno, J.; Dirbas, F. M.; Goswami, S.; Somlo, G.; Condeelis, J.; Contag, C. H.; Gambhir, S. S.; Clarke, M. F. *Proc. Natl. Acad. Sci. U. S. A.* **2010**, *107*, 18115–18120.
- (12) Robertson, R.; Germanos, M. S.; Manfredi, M. G.; Smith, P. G.; Silva, M. D. *J. Nucl. Med.* **2011**, *52*, 1764–1769.
- (13) Caprioli, R. M.; Farmer, T. B.; Gile, J. *Anal. Chem.* **1997**, *69*, 4751–4760.
- (14) Ellis, S. R.; Cappell, J.; Potocnik, N. O.; Balluff, B.; Hamaide, J.; Van der Linden, A.; Heeren, R. M. A. *Analyst* **2016**, *141*, 3832–3841.
- (15) Dillillo, M.; Ait-Belkacem, R.; Esteve, C.; Pellegrini, D.; Nicolardi, S.; Costa, M.; Vannini, E.; Graaf, E. L.; Caleo, M.; McDonnell, L. A. *Sci. Rep.* **2017**, *7*, 603.
- (16) Barre, F. P.; Flinders, B.; Garcia, J. P.; Jansen, I.; Huizing, L. R.; Porta, T.; Creemers, L. B.; Heeren, R. M.; Cillero-Pastor, B. *Anal. Chem.* **2016**, *88*, 12051–12059.
- (17) Sans, M.; Gharpure, K.; Tibshirani, R.; Zhang, J.; Liang, L.; Liu, J.; Young, J. H.; Dood, R. L.; Sood, A. K.; Eberlin, L. S. *Cancer Res.* **2017**, *77*, 2903–2913.
- (18) Delcourt, V.; Franck, J.; Leblanc, E.; Narducci, F.; Robin, Y. M.; Gimeno, J. P.; Quanicco, J.; Wisztorski, M.; Kobeissy, F.; Jacques, J. F.; Roucou, X.; Salzet, M.; Fournier, I. *EBioMedicine* **2017**, *21*, 55–64.
- (19) Caprioli, R. M.; Farmer, T. B.; Zhang, H. Y.; Stoeckli, M. *Abstr Pap Am. Chem. S* **1997**, *214*, 113–ANYL.
- (20) Feenstra, A. D.; Duenas, M. E.; Lee, Y. J. *J. Am. Soc. Mass Spectrom.* **2017**, *28*, 434–442.
- (21) Zavalin, A.; Yang, J.; Hayden, K.; Vestal, M.; Caprioli, R. M. *Anal. Bioanal. Chem.* **2015**, *407*, 2337–2342.
- (22) Prentice, B. M.; Chumbley, C. W.; Caprioli, R. M. *J. Mass Spectrom.* **2015**, *50*, 703–710.
- (23) Hinsenkamp, I.; Schulz, S.; Roscher, M.; Suhr, A. M.; Meyer, B.; Munteanu, B.; Fuchser, J.; Schoenberg, S. O.; Ebert, M. P. A.; Wangler, B.; Hopf, C.; Burgermeister, E. *Neoplasia* **2016**, *18*, 500–511.
- (24) Jiang, W. G.; Davies, G.; Martin, T. A.; Parr, C.; Watkins, G.; Mansel, R. E.; Mason, M. D. *Int. J. Mol. Med.* **2006**, *16*, 723–728.
- (25) Damas, N. D.; Marcatti, M.; Come, C.; Christensen, L. L.; Nielsen, M. M.; Baumgartner, R.; Gylling, H. M.; Maglieri, G.; Rundsten, C. F.; Seemann, S. E.; Rapin, N.; Thezenas, S.; Vang, S.; Orntoft, T.; Andersen, C. L.; Pedersen, J. S.; Lund, A. H. *Nat. Commun.* **2016**, *7*, 13875.
- (26) Ansell, S. M.; Arendt, B. K.; Grote, D. M.; Jelinek, D. F.; Novak, A. J.; Wellik, L. E.; Remstein, E. D.; Bennett, C. F.; Fielding, A. *Leukemia* **2004**, *18*, 616–623.
- (27) Mori, F.; Ishida, T.; Ito, A.; Sato, F.; Masaki, A.; Takino, H.; Ri, M.; Kusumoto, S.; Komatsu, H.; Ueda, R.; Inagaki, H.; Iida, S. *Blood Cancer Journal* **2012**, *2*, e67.
- (28) Bakker, B.; Eijkel, G. B.; Heeren, R. M. A.; Karperien, M.; Post, J. N.; Cillero-Pastor, B. *Anal. Chem.* **2017**, *89*, 9438–9444.
- (29) Eijkel, G. B.; Kaletas, B. K.; van der Wiel, I. M.; Kros, J. M.; Luiders, T. M.; Heeren, R. M. A. *Surf. Interface Anal.* **2009**, *41*, 675–685.
- (30) Hoogerbrugge, R.; Willig, S. J.; Kistemaker, P. G. *Anal. Chem.* **1983**, *55*, 1710–1712.
- (31) Ellis, S. R.; Paine, M. R. L.; Eijkel, G. B.; Pauling, J. K.; Husen, P.; Jervelund, M. W.; Hermansson, M.; Ejsing, C. S.; Heeren, R. M. A. *Nat. Methods* **2018**, *15*, 515.
- (32) Mahadevan, D.; Morales, C.; Cooke, L. S.; Manziello, A.; Mount, D. W.; Persky, D. O.; Fisher, R. I.; Miller, T. P.; Qi, W. *PLoS One* **2014**, *9*, No. e95184.
- (33) Coiffier, B.; Sarkozy, C. *Hematology/the Education Program of the American Society of Hematology. American Society of Hematology. Education Program* **2016**, 2016, 366–378.
- (34) Uddin, S.; Hussain, A. R.; Siraj, A. K.; Manogaran, P. S.; Al-Jomah, N. A.; Moorji, A.; Atizado, V.; Al-Dayel, F.; Belgaumi, A.; El-Solh, H.; Ezzat, A.; Bavi, P.; Al-Kuraya, K. S. *Blood* **2006**, *108*, 4178–4186.
- (35) Dreyling, M.; Santoro, A.; Mollica, L.; Leppa, S.; Follows, G. A.; Lenz, G.; Kim, W. S.; Nagler, A.; Panayiotidis, P.; Demeter, J.; Ozcan, M.; Kosinova, M.; Bouabdallah, K.; Morschhauser, F.; Stevens, D. A.; Trevarthen, D.; Giurescu, M.; Cupit, L.; Liu, L.; Kochert, K.; Seidel, H.; Pena, C.; Yin, S.; Hiemeyer, F.; Garcia-Vargas, J.; Childs, B. H.; Zinzani, P. L. *J. Clin. Oncol.* **2017**, *35*, 3898–3905.
- (36) Chughtai, K.; Jiang, L.; Greenwood, T. R.; Glunde, K.; Heeren, R. M. A. *J. Lipid Res.* **2013**, *54*, 333–344.
- (37) Irigoyen, M.; Garcia-Ruiz, J. C.; Berra, E. *Oncotarget* **2017**, *8*, 36832–36844.
- (38) Amstalden van Hove, E. R.; Blackwell, T. R.; Klinkert, I.; Eijkel, G. B.; Heeren, R. M.; Glunde, K. *Cancer Res.* **2010**, *70*, 9012–9021.
- (39) Glunde, K.; Jacobs, M. A.; Bhujwalla, Z. M. *Expert Rev. Mol. Diagn.* **2006**, *6*, 821–829.
- (40) Summers, R. M.; Joseph, P. M.; Kundel, H. L. *Invest. Radiol.* **1991**, *26*, 233–241.
- (41) Wang, J.; Qiu, S.; Chen, S.; Xiong, C.; Liu, H.; Wang, J.; Zhang, N.; Hou, J.; He, Q.; Nie, Z. *Anal. Chem.* **2015**, *87*, 422–430.
- (42) Ly, A.; Buck, A.; Balluff, B.; Sun, N.; Gorzalka, K.; Feuchtinger, A.; Janssen, K. P.; Kuppen, P. J.; van de Velde, C. J.; Weirich, G.; Erlmeier, F.; Langer, R.; Aubele, M.; Zitzelsberger, H.; McDonnell, L.; Aichler, M.; Walch, A. *Nat. Protoc.* **2016**, *11*, 1428–1443.
- (43) Fang, M.; Shen, Z. R.; Huang, S.; Zhao, L. P.; Chen, S.; Mak, T. W.; Wang, X. D. *Cell* **2010**, *143*, 711–724.
- (44) Zheng, J. *Oncol. Lett.* **2012**, *4*, 1151–1157.
- (45) Kiebish, M. A.; Han, X.; Cheng, H.; Chuang, J. H.; Seyfried, T. N. *J. Lipid Res.* **2008**, *49*, 2545–2556.
- (46) Xu, H. N.; Mir, T. A.; Lee, S. C.; Feng, M.; Farhad, N.; Choe, R.; Glickson, J. D.; Li, L. Z. *Adv. Exp. Med. Biol.* **2013**, *789*, 243–249.
- (47) Xu, H. N.; Zhao, H.; Mir, T. A.; Lee, S. C.; Feng, M.; Choe, R.; Glickson, J. D.; Li, L. Z. *J. Innovative Opt. Health Sci.* **2013**, *06*, 1350011.
- (48) Xiong, J.; Bian, J.; Wang, L.; Zhou, J. Y.; Wang, Y.; Zhao, Y.; Wu, L. L.; Hu, J. J.; Li, B.; Chen, S. J.; Yan, C.; Zhao, W. L. *Blood Cancer J.* **2015**, *5*, e287.
- (49) Glunde, K.; Penet, M. F.; Jiang, L.; Jacobs, M. A.; Bhujwalla, Z. M. *Expert Rev. Mol. Diagn.* **2015**, *15*, 735–747.
- (50) Moestue, S. A.; Giskeodegard, G. F.; Cao, M. D.; Bathen, T. F.; Gribbestad, I. S. *Proc. Natl. Acad. Sci. U. S. A.* **2012**, *109*, E2506.
- (51) Hamm, G.; Bonnel, D.; Legouffe, R.; Pamelard, F.; Delbos, J. M.; Bouzom, F.; Stauber, J. *J. Proteomics* **2012**, *75*, 4952–4961.
- (52) Taylor, A. J.; Dexter, A.; Bunch, J. *Anal. Chem.* **2018**, *90*, 5637–5645.